Izotropic Corporation has filed a preliminary prospectus in connection with its initial public offering of a minimum of 2,000,000 common shares at a price of $0.10 per common share for gross proceeds of $200,000
Chippingham Financial Group Limited acts as agent for the offering. Clark Wilson LLP and McCullough O’Connor Irwin LLP are acting as legal counsels to Izotropic and agent respectively.
Izotropic Corporation has applied to list its shares on the Canadian Securities Exchange (CSE).
Founded in 2016, Izotropic is engaged in the commercialization of proprietary diagnostic products for breast cancer.
Izotropic Corporation, through its US subsidiary, Isotropic Imaging Corporation, signed a licensing agreement with University of California, Davis (UC Dadvis) for the rights to commercialize a novel computed tomography (CT) scanner that has the potential to improve breast cancer detection and positively impact women’s health. The technology was developed at UC Davis by a team led by Dr. John Boone, Professor of Radiology and a member of the UC Davis Comprehensive Cancer Center. The primary advantage of the scanner is that it provides true three-dimensional and highly-detailed images of the human breast, offering a less obstructed view of potential lesions than provided by current two-dimensional mammograms.
Dr. Boone serves as director on Izotropic board.
Led by Robert Thast, CEO & director, Izotropic has raised $1.16 million in equity funding in the last 12 months. Izotropic currently has 20,499,999 common shares issued and outstanding.
photo credit: UC Davis, Dr. Boone